You are here

Article Text

Article menu
Download PDFPDF
Introduction
Myocardial perfusion scintigraphy in the UK: how much are we doing and how can we do more?
  1. Andrew D Kelion,
  2. S Richard Underwood
  1. on behalf of the British Nuclear Cardiology Societya.kelion@rbh.nthames.nhs.uk

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Myocardial perfusion scintigraphy (MPS) has been available as an investigation in known or suspected coronary artery disease for 30 years. In the USA, it is an established first line diagnostic and prognostic tool alongside the exercise ECG, and this is reflected in a high level of activity (35 000 studies per million population per year in 2002; Philips Medical Systems, personal communication). In Europe, and particularly in the UK, MPS has tended to be a second line investigation reserved for patients for whom coronary angiography is considered unattractive, and activity levels are correspondingly lower.1

    In the UK, the National Institute …

    View Full Text